ImmunoCellular Therapeutics ($IMUC) licenses EphA2 from University of Pittsburgh 
Thursday, March 22, 2012 at 8:13AM
DDE Editor in Oncology, dndn, imuc, prima biomed

ImmunoCellular Therapeutics (OTCBB: IMUC) has entered into an agreement with University of Pittsburgh under where Pitt has licensed intellectual property to the company surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies.

This agreement grants a world-wide exclusive license to the Pitt intellectual property for ovarian and pancreatic cancers, and a world-wide non-exclusive license to the Pitt intellectual property for brain cancer.

Financial terms of the agreement were not disclosed. The company will employ the Pitt intellectual property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer.

Please see our other post(s) on IMUC, PrimaBioMed and Merck KG (StimuVax).

View the full IMUC chart at Wikinvest
Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).
See website for complete article licensing information.